Analysis of mass spectrometry data for serum biomarker discovery

被引:0
|
作者
Ressom, Habtom W. [1 ]
Varghese, Rency S. [1 ]
Goldman, Lenka [1 ]
Loffredo, Christopher A. [1 ]
Abdel-Hamid, Mohamed [2 ,3 ]
Kyselova, Zuzana [4 ]
Mechref, Yehia [4 ]
Novotny, Milos [4 ]
Goldman, Radoslav [1 ]
机构
[1] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA
[2] Menia Univ, Cairo, Egypt
[3] NHTMRI, Viral Hepatitis Res Lab, Cairo, Egypt
[4] Natl Ctr Glycom & Glycoproteom, Dept Chem, Bloomington, IN USA
来源
2007 IEEE/NIH LIFE SCIENCE SYSTEMS AND APPLICATIONS WORKSHOP | 2007年
关键词
D O I
10.1109/LSSA.2007.4400912
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
We present a computational framework to analyze MALDI-TOF mass spectrometry data for quantitative comparison of peptides and glycans in serum. In particular, we introduce an algorithm that detects peaks that are differentially abundant in a subgroup of patients. The method is applied to identify candidate biomarkers in serum samples of 203 participants from Egypt; 73 hepatocellular carcinoma (HCC) cases, 52 patients with chronic liver disease (CLD), and 78 healthy individuals. Mass spectra were generated using two experiments: (1) low molecular weight (LMW) enriched serum samples were used for MALDI-TOF quantification of peptides, and (2) glycans were enzymatically released from proteins in serum and permethylated prior to MALDI-TOF quantification. A subset of the participants (35 HCC and 35 CLD cases) was used to select the most useful peaks. The peak selection step is preceded by peak screening, where we eliminated peaks that seem to have association with covariates such as age, gender, and viral infection based on the 78 spectra from healthy individuals. The performance of the selected peaks was evaluated in terms of detecting the disease state of a blinded independent set that comprised of 38 HCC and 17 CLD cases. Further evaluation of the potential clinical utility of the selected candidate peptide and glycan markers is needed.
引用
收藏
页码:172 / +
页数:2
相关论文
共 50 条
  • [21] Sample preparation and fractionation for proteome analysis and cancer biomarker discovery by mass spectrometry
    Ahmed, Farid E.
    JOURNAL OF SEPARATION SCIENCE, 2009, 32 (5-6) : 771 - 798
  • [22] Biomarker discovery by imperialist competitive algorithm in mass spectrometry data for ovarian cancer prediction
    Pirhadi, Shiva
    Maghooli, Keivan
    Moteghaed, Niloofar Yousefi
    Garshasbi, Masoud
    Mousavirad, Seyed Jalaleddin
    JOURNAL OF MEDICAL SIGNALS & SENSORS, 2021, 11 (02): : 108 - 119
  • [23] TOFwave: reproducibility in biomarker discovery from time-of-flight mass spectrometry data
    Chierici, Marco
    Albanese, Davide
    Franceschi, Pietro
    Furlanello, Cesare
    MOLECULAR BIOSYSTEMS, 2012, 8 (11) : 2845 - 2849
  • [24] Lung Cancer Serum Biomarker Discovery Using Glycoprotein Capture and Liquid Chromatography Mass Spectrometry
    Zeng, Xuemei
    Hood, Brian L.
    Sun, Mai
    Conrads, Thomas P.
    Day, Roger S.
    Weissfeld, Joel L.
    Siegfried, Jill M.
    Bigbee, William L.
    JOURNAL OF PROTEOME RESEARCH, 2010, 9 (12) : 6440 - 6449
  • [25] Mass spectrometry based proteomics in urine biomarker discovery
    Dan Theodorescu
    Harald Mischak
    World Journal of Urology, 2007, 25 : 435 - 443
  • [26] Advancing cerebrospinal fluid biomarker discovery by mass spectrometry
    Gobom, Johan
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2015, 5 (05) : 371 - 373
  • [27] Mass spectrometry based proteomics in urine biomarker discovery
    Theodorescu, Dan
    Mischak, Harald
    WORLD JOURNAL OF UROLOGY, 2007, 25 (05) : 435 - 443
  • [28] Adaptive bandwidth selection for biomarker discovery in mass spectrometry
    Fischer, Bernd
    Roth, Volker
    Buhmann, Joachim M.
    ARTIFICIAL INTELLIGENCE IN MEDICINE, 2009, 45 (2-3) : 207 - 214
  • [29] The Role of Mass Spectrometry in Hepatocellular Carcinoma Biomarker Discovery
    Shen, Eric Yi-Liang
    Abellona, U. Mei Ran
    Cox, I. Jane
    Taylor-Robinson, Simon D.
    METABOLITES, 2023, 13 (10)
  • [30] MALDI mass spectrometry in prostate cancer biomarker discovery
    Flatley, Brian
    Malone, Peter
    Cramer, Rainer
    BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2014, 1844 (05): : 940 - 949